Deacetylase Inhibitor News and Research

RSS

Combining inhibitor drug with immunotherapy agent improves response in cancer patients

Combining a histone deacetylase inhibitor drug with immunotherapy agents is safe, and may benefit some patients with advanced cancers that have not responded to traditional therapy, according to results of a phase 1 clinical trial led by researchers at the Johns Hopkins Kimmel Cancer Center, Bloomberg~Kimmel Institute for Cancer Immunotherapy and several other centers including University of Pittsburgh Cancer Institute, Yale Cancer Center and City of Hope in Los Angeles, which participated in study enrollment, and the University of Southern California and University College Cork in Ireland, which collaborated on analysis of the data.

16 Aug 2021

New drug combination improves blood glucose control and weight loss in mice

Scientists have shown that adding an experimental cancer drug to a widely used diabetes treatment improves blood glucose control and weight loss in mice, according to a study published today in eLife.

22 Dec 2020

New research finds how cancer cells acquire resistance to molecular-targeted drugs

Although molecular-targeted drugs have been known to show high efficacy to lung cancer patients, they also have limitations due to acquiring resistance to the drug used.

25 Feb 2019

Novel drug combination could enhance immunotherapy responses in patients with lung cancer

Johns Hopkins Kimmel Cancer Center researchers and colleagues have identified a novel drug combination therapy that could prime nonsmall cell lung cancers to respond better to immunotherapy.

30 Nov 2017

Radiotherapy plus panobinostat more effective for aggressive, recurrent brain cancer

Radiotherapy effectively damages brain tumors but the cancer cells can repair themselves in order to live on. Now, researchers at Sidney Kimmel Cancer Center have tested a strategy that combines radiotherapy with a drug that shuts down the ability of tumor to mend themselves.

27 Feb 2016

Researchers use stem cell-derived 'mini-brains' to identify drug candidate for rare neurological disorder

Using "mini-brains" built with induced pluripotent stem cells derived from patients with a rare, but devastating, neurological disorder, researchers at University of California, San Diego School of Medicine say they have identified a drug candidate that appears to "rescue" dysfunctional cells by suppressing a critical genetic alteration.

9 Sep 2015

FDA accepts Mundipharma EDO's Investigational New Drug Application for EDO-S101

Mundipharma EDO GmbH (Early Development in Oncology) is pleased to announce that the United States Food and Drug Administration has accepted the company's Investigational New Drug Application ("IND") for EDO-S101, a fusion molecule to treat relapsed/refractory haematologic malignancies and solid tumours.

31 Jul 2015

Novartis presents positive Phase III results of Farydak therapy at EHA

Novartis today presented results from a pivotal Phase III clinical trial exploratory subgroup analysis showing a 7.8-month improvement in median progression-free survival when using Farydak in combination with bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who had received two or more prior regimens, including bortezomib and an immunomodulatory agent.

16 Jun 2015

Arno Therapeutics' AR-42 with cisplatin demonstrates anti-tumor effect in bladder cancer models

Arno Therapeutics, Inc., a clinical stage biopharmaceutical company primarily focused on the development of oncology therapeutics, today announced that data from a preclinical study demonstrate its histone-deacetylase (HDAC) inhibitor AR-42 in combination with cisplatin has a synergistic anti-tumor effect in bladder cancer models.

26 Mar 2015

Novel therapeutic approaches to improve thyroid cancer outcomes

Novel therapeutic approaches to improve outcomes in thyroid cancer, for example using targeted delivery of cytotoxic drugs to tumor cells, will be among the topics featured in oral and poster presentations delivered at the 84th Annual Meeting of the American Thyroid Association, October 29-November 2, 2014, in Coronado, California.

30 Oct 2014

FDA grants Breakthrough Therapy designation to Syndax's entinostat for ER+ breast cancer

Syndax Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration has designated entinostat as a Breakthrough Therapy for the treatment of locally recurrent or metastatic estrogen receptor-positive (ER+) breast cancer when added to exemestane in postmenopausal women whose disease has progressed following non-steroidal aromatase inhibitor therapy.

12 Sep 2013

Researchers discover new approach to treat two lethal metastatic cancers

A potentially powerful new approach to treating two lethal metastatic cancers - triple negative breast cancer and clear cell renal cell carcinoma, the most common form of kidney cancer - has been discovered by researchers at Mayo Clinic in Florida.

1 Aug 2012

Lymphoma drug dislodges hidden virus in HIV patients

Researchers from the University of North Carolina at Chapel Hill have published pioneering research showing that a drug used to treat certain types of lymphoma was able to dislodge hidden virus in patients receiving treatment for HIV.

27 Jul 2012

MD Anderson initiates Phase 1/2 entinostat-lapatinib ditosylate combination study in metastatic breast cancer

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announced that investigators at The University of Texas MD Anderson Cancer Center Department of Breast Medical Oncology have initiated a phase 1/2 study combining Syndax's lead product entinostat with lapatinib ditosylate (Tykerb) in patients with locally recurrent or distant relapsed metastatic breast cancer previously treated with trastuzumab (Herceptin).

9 Apr 2012

NYUCI experts present latest research findings about hematologic cancers at 53rd ASH meeting

Experts from the NYU Cancer Institute, an NCI-designated cancer center at NYU Langone Medical Center, presented their latest research findings about hematologic cancers at the 53rd ASH Annual Meeting and Exposition held December 10-13, 2011 in San Diego, California.

14 Dec 2011

Vorinostat in addition to chemotherapy drugs improves remission rates in AML patients

Adding a drug that activates genes to frontline combination therapy for acute myeloid leukemia resulted in an 85 percent remission rate after initial treatment, researchers at The University of Texas MD Anderson Cancer Center reported at the 53rd Annual Meeting of the American Society of Hematology.

14 Dec 2011

Researchers show how ER-positive breast cancer tumors become resistant to tamoxifen

Researchers have shown how estrogen receptor-positive breast cancer tumors become resistant to tamoxifen, the only approved hormonal therapy for premenopausal patients with this type of breast cancer.

14 Nov 2011

Combination of azacitidine and entinostat shows promise against NSCLC

A new type of therapy aimed at reversing the gene-silencing that promotes cancer-cell growth has shown promising results in a small clinical trial conducted by researchers at the Johns Hopkins Kimmel Cancer Center.

10 Nov 2011

Syndax receives European patent allowance for entinostat to treat metastatic breast cancer

Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, today announced allowance by the European Patent Office for the patent application titled "N-(2-AMINOPHENYL)-4[N-(PYRIDINE-3-YL) - METHOXYCARBONYL - AMINOMETHYL]-BENZAMINE (MS-275) POLYMORPH B."

18 Aug 2011

Syndax receives U.S. patent for entinostat to treat metastatic cancers

Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, today announced allowance by the United States Patent and Trademark Office of Patent Application Serial No. 12/549458 entitled: " N-(2-AMINOPHENYL)-4[N-(PYRIDINE-3-YL)- METHOXYCARBONYL—AMINOMETHYL]-BENZAMINE (MS-275) POLYMORPH B."

3 Jun 2011